You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

VIGABATRIN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for vigabatrin and what is the scope of patent protection?

Vigabatrin is the generic ingredient in five branded drugs marketed by Lundbeck Pharms Llc, Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Annora Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Dexcel, Dr Reddys, Endo Operations, Granules, Invagen Pharms, MSN, Propel Pharma, Specgx Llc, Teva Pharms Usa, Zydus Lifesciences, Aucta, Pyros Pharms, Hikma, Ryan Labs, and Upsher Smith Labs, and is included in thirty NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Vigabatrin has three patent family members in two countries.

There are five drug master file entries for vigabatrin. Seventeen suppliers are listed for this compound.

Summary for VIGABATRIN
International Patents:3
US Patents:1
Tradenames:5
Applicants:22
NDAs:30
Drug Master File Entries: 5
Finished Product Suppliers / Packagers: 17
Raw Ingredient (Bulk) Api Vendors: 121
Clinical Trials: 30
Patent Applications: 5,913
Drug Prices: Drug price trends for VIGABATRIN
What excipients (inactive ingredients) are in VIGABATRIN?VIGABATRIN excipients list
DailyMed Link:VIGABATRIN at DailyMed
Drug Prices for VIGABATRIN

See drug prices for VIGABATRIN

Recent Clinical Trials for VIGABATRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AmzellPhase 3
University of FloridaPhase 2
Yale UniversityPhase 2

See all VIGABATRIN clinical trials

Pharmacology for VIGABATRIN
Medical Subject Heading (MeSH) Categories for VIGABATRIN
Anatomical Therapeutic Chemical (ATC) Classes for VIGABATRIN

US Patents and Regulatory Information for VIGABATRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dexcel VIGABATRIN vigabatrin TABLET;ORAL 215109-001 Sep 23, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msn VIGABATRIN vigabatrin FOR SOLUTION;ORAL 215363-001 Sep 7, 2022 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Propel Pharma VIGABATRIN vigabatrin FOR SOLUTION;ORAL 213390-001 Jul 29, 2021 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx VIGABATRIN vigabatrin FOR SOLUTION;ORAL 211790-001 Mar 10, 2022 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VIGABATRIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
ORPHELIA Pharma SAS Kigabeq vigabatrin EMEA/H/C/004534
Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.
Authorised no no no 2018-09-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.